Scotiabank initiated coverage of CG Oncology (CGON) with a Sector Perform rating and $23 price target The company is developing a novel ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer ... Another potential rival - CG Oncology's retostimogene grenadenorepvec ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer ... could also be on the way from CG Oncology, a recent Nasdaq debutante whose ...

Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

Fintel reports that on April 16, 2025, Scotiabank initiated coverage of CG Oncology (NasdaqGS:CGON) with a Sector Perform ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The following is a summary of “Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal transition and promote bladder cancer progression,” published in the April 2025 issue of BMC ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...